| Literature DB >> 23082199 |
Menno R van den Bergh1, Giske Biesbroek, John W A Rossen, Wouter A A de Steenhuijsen Piters, Astrid A T M Bosch, Elske J M van Gils, Xinhui Wang, Chantal W B Boonacker, Reinier H Veenhoven, Jacob P Bruin, Debby Bogaert, Elisabeth A M Sanders.
Abstract
BACKGROUND: High rates of potentially pathogenic bacteria and respiratory viruses can be detected in the upper respiratory tract of healthy children. Investigating presence of and associations between these pathogens in healthy individuals is still a rather unexplored field of research, but may have implications for interpreting findings during disease. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2012 PMID: 23082199 PMCID: PMC3474735 DOI: 10.1371/journal.pone.0047711
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the children, nasopharyngeal bacterial colonization and viral detection rates.
| Characteristic | 6-month-old children | 12-month-old children | 18-month-old children | 24-month-old children | Total |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Number of samples (children) | 288 | 198 | 298 | 202 | 986 |
| Age, months (SD) | 6.1 (0.39) | 12.1 (0.41) | 18.1 (0.35) | 24.3 (0.69) | NA |
| Period of sampling | NA | ||||
| From: | November 2005 | October 2006 | December 2006 | September 2007 | |
| To; | June 2006 | January 2007 | July 2007 | January 2008 | |
| Male sex | 162 (56) | 105 (53) | 162 (54) | 107 (52) | 536 (54) |
| PCV-7 vaccination | 146 (51) | 104 (53) | 149 (50) | 98 (49) | 497 (50) |
| Day care attendance | 159 (55) | 127 (64) | 186 (62) | 149 (74) | 621 (63) |
| Presence of siblings | 142 (49) | 106 (54) | 157 (53) | 130 (64) | 535 (54) |
| Recent antibiotic use | 22 (8) | 23 (12) | 35 (12) | 11 (5) | 91 (9) |
| Symptoms of URTI | 71 (25) | 79 (40) | 102 (34) | 76 (38) | 328 (33) |
|
| |||||
| Any bacterium | 250 (87) | 185 (93) | 278 (93) | 187 (93) | 900 (91) |
| Multiple bacteria | 173 (60) | 150 (76) | 204 (69) | 142 (70) | 639 (65) |
|
| 143 (50) | 139 (70) | 191 (64) | 134 (66) | 607 (62) |
|
| 99 (34) | 103 (52) | 179 (60) | 115 (57) | 496 (50) |
|
| 190 (66) | 158 (80) | 215 (72) | 148 (73) | 711(72) |
|
| 47 (16) | 13 (7) | 14 (5) | 11 (5) | 85 (9) |
|
| |||||
| Any virus | 168 (58) | 146 (74) | 209 (70) | 140 (69) | 663 (67) |
| Multiple viruses | 53 (18) | 76 (38) | 91 (31) | 65 (32) | 285 (29) |
| Human rhinovirus | 88 (31) | 98 (50) | 104 (35) | 80 (40) | 370 (38) |
| Enterovirus | 6 (2) | 42 (21) | 37 (26) | 43 (21) | 128 (15) |
| Human bocavirus | 26 (9) | 17 (9) | 53 (18) | 27 (13) | 123 (12) |
| Polyomaviruses (pooled) | 30 (10) | 33 (17) | 43 (14) | 41 (20) | 147 (15) |
| WU | 16 (6) | 28 (14) | 34 (11) | 33 (16) | 111 (11) |
| KI | 14 (5) | 5 (3) | 9 (3) | 8 (4) | 36 (4) |
| Human coronaviruses (pooled) | 23 (8) | 6 (3) | 31 (10) | 20 (10) | 80 (8) |
| OC43 | 6 (2) | 5 (3) | 22 (7) | 0 (0) | 33 (3) |
| NL63 | 6 (2) | 1 (1) | 6 (2) | 3 (1) | 16 (2) |
| HKU | 5 (2) | 0 (0) | 3 (1) | 7 (3) | 15 (2) |
| 229E | 2 (1) | 0 (0) | 0 (0) | 5 (2) | 7 (1) |
| Unknown | 4 (1) | 0 (0) | 0 (0) | 5 (2) | 9 (1) |
| Parainfluenza viruses (pooled) | 14 (5) | 10 (5) | 31 (10) | 7 (4) | 62 (6) |
| Type 1 | 9 (3) | 0 (0) | 20 (7) | 1 (0) | 30 (3) |
| Type 2 | 1 (0) | 0 (0) | 0 (0) | 2 (1) | 3 (0) |
| Type 3 | 3 (1) | 1 (1) | 6 (2) | 0 (0) | 10 (1) |
| Type 4 | 0 (0) | 9 (5) | 5 (2) | 3 (1) | 17 (2) |
| Unknown | 1 (0) | 0 (0) | 0 (0) | 1 (0) | 2 (0) |
| Human adenovirus | 15 (5) | 11 (6) | 23 (8) | 9 (5) | 58 (6) |
| Human parechovirus | 14 (5) | 29 (15) | 9 (6) | 19 (9) | 71 (9) |
| Respiratory syncytial virus | 6 (2) | 5 (3) | 9 (3) | 5 (3) | 25 (3) |
| Influenza virus | 11 (4) | 2 (1) | 3 (1) | 1 (1) | 17 (2) |
| Human metapneumovirus | 2 (1) | 1 (1) | 1 (0) | 0 (0) | 4 (0) |
Abbreviations: SD, standard deviation; NA, not applicable; PCV-7, 7-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection.
Defined as more than 4 hours per week with at least one child from another family (yes/no).
Defined as use of an antibiotic, orally or intravenously administered with start date within 2 months before sampling date (yes/no). Of those, the prescribed antibiotic was amoxicillin (n = 69), penicillin (n = 1), amoxicillin/clavulanic acid (n = 3), a macrolide (n = 14; claritromycin (n = 8), azitromycin (n = 5), erythromycin (n = 1), a cephalosporin (n = 1, unknown type), and 3 unknowns.
Parent-reported presence of mild symptoms of an upper respiratory tract infection (eg, a runny nose) at the time of sampling (yes/no).
Presence of enteroviruses and human parechovirus was determined in a subgroup of samples (N = 831) due to insufficient amounts of remaining nasopharyngeal swab material or nucleic acids to run these tests. Missing values were imputed by the single imputation procedure in multivariate analysis models in which these viruses were included to retain statistical power.
Distribution and adjusted odds ratiosa,b for nasopharyngeal bacterial colonization, co-occurrence with each of the other bacteria, respiratory viruses and risk factors.
|
|
|
|
| |||||||||
| Covariate | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||||
|
| NA | 139 (37) | 357 (59) |
| 226 (60) | 485 (80) |
| 51 (13) | 34 (6) |
| ||
|
| 250 (51) | 357 (72) |
| NA | 318 (65) | 393 (79) | 1.24 (0.89–1.72) | 57 (12) | 28 (6) | 0.72 (0.44–1.21) | ||
|
| 122 (44) | 485 (68) |
| 103 (37) | 393 (55) |
| NA | 45 (16) | 40 (6) |
| ||
|
| 573 (64) | 34 (40) |
| 468 (52) | 28 (33) | 0.72 (0.43–1.23) | 671 (74) | 40 (47) |
| NA | ||
| Antibiotic use | 574 (64) | 33 (36) |
| 450 (50) | 46 (51) | NA | 643 (72) | 68 (75) | NA | 75 (8) | 10 (11) | NA |
| Presence of siblings | 236 (52) | 371 (69) |
| 181 (40) | 315 (59) |
| 309 (69) | 402 (75) |
| 46 (10) | 39 (7) | NA |
| Day care attendance | 183 (50) | 424 (68) |
| 130 (36) | 366 (59) |
| 202 (55) | 509 (82) |
| 47 (13) | 38 (6) | 0.74 (0.45–1.21) |
| PCV-7 vaccination | 326 (65) | 281 (58) |
| 248 (50) | 248 (51) | NA | 372 (75) | 339 (70) | NA | 40 (8) | 45 (9) | NA |
| Human rhinovirus | 335 (54) | 272 (74) |
| 267 (43) | 229 (62) |
| 420 (68) | 291 (79) | 1.21 (0.86–1.69) | 54 (9) | 31 (8) | NA |
| Enterovirus | 471 (58) | 136 (79) |
| 382 (47) | 114 (66) | 1.25 (0.84–1.85) | 568 (70) | 143 (83) | 1.27 (0.79–2.05) | 74 (9) | 11 (6) | NA |
| Human bocavirus | 527 (61) | 80 (65) | NA | 424 (49) | 72 (59) | 1.11 (0.73–1.70) | 615 (71) | 96 (78) | NA | 78 (9) | 7 (6) | NA |
| WU polyomavirus | 529 (60) | 78 (70) | 1.32 (0.82–2.14) | 430 (49) | 66 (59) | 1.17 (0.75–1.83) | 629 (72) | 82 (74) | NA | 78 (9) | 7 (6) | NA |
| Human coronavirus | 550 (61) | 57 (71) | 1.38 (0.80–2.38) | 456 (50) | 40 (50) | NA | 642 (71) | 69 (86) |
| 82 (9) | 3 (4) | NA |
| Parainfluenza virus | 568 (60) | 39 (63) | NA | 470 (51) | 26 (42) | NA | 662 (72) | 49 (79) | NA | 83 (9) | 2 (3) | NA |
| Adenovirus | 561 (60) | 46 (79) | 1.91 (0.95–3.84) | 462 (50) | 34 (59) | NA | 657 (76) | 54 (93) |
| 83 (9) | 2 (3) | NA |
| Human parechovirus | 530 (60) | 77 (76) | NA | 434 (49) | 62 (61) | 1.19 (0.75–1.90) | 630 (71) | 81 (80) | 1.17 (0.67–2.05) | 76 (9) | 9 (9) | NA |
| KI polyomavirus | 586 (62) | 21 (58) | NA | 482 (50) | 14 (39) | NA | 683 (72) | 28 (78) | NA | 84 (9) | 1 (3) | NA |
| RSV | 590 (61) | 17 (68) | NA | 478 (50) | 18 (72) |
| 694 (72) | 17 (68) | NA | 83 (9) | 2 (8) | NA |
| Influenza virus | 596 (62) | 11 (65) | NA | 487 (50) | 9 (53) | NA | 701 (72) | 10 (59) | NA | 79 (8) | 6 (35) |
|
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; NA, not applicable (i.e., not included in the model for that particular bacterial pathogen), RSV, respiratory syncytial virus.
Adjusted for age and all variables with a P value of <0.1 in univariate analysis.
Statistically significant associations are shown in bold.
Distribution and adjusted odds ratiosa,b for nasopharyngeal presence of the most common viruses, co-occurrence with each of the other respiratory viruses, bacteria and risk factors.
| Human rhinovirus | Enterovirus | Human bocavirus | WU polyomavirus | |||||||||
| Covariate | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) | Without covariate | With covariate | aOR (95% CI) |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||||
|
| 98 (26) | 272 (45) |
| 36 (9) | 136 (22) |
| 43 (11) | 80 (13) | NA | 33 (9) | 78 (13) | 1.30 (0.82–2.06) |
|
| 141 (29) | 229 (46) |
| 58 (12) | 114 (23) | 1.26 (0.85–1.87) | 51 (10) | 72 (15) | 1.07 (0.71–1.63) | 45 (9) | 66 (13) | 1.13 (0.73–1.75) |
|
| 79 (29) | 291 (41) | 1.22 (088–1.70) | 29 (11) | 143 (20) | 1.30 (0.80–2.11) | 27 (10) | 96 (14) | NA | 29 (11) | 82 (12) | NA |
|
| 339 (38) | 31 (36) | NA | 161 (18) | 11 (13) | NA | 116 (13) | 7 (8) | NA | 104 (12) | 7 (8) | NA |
| Antibiotic use | 343 (38) | 27 (30) | NA | 153 (17) | 19 (21) | NA | 107 (12) | 16 (3) | NA | 101 (12) | 10 (11) | NA |
| Presence of siblings | 146 (32) | 224 (42) |
| 75 (17) | 97 (18) | NA | 62 (14) | 61 (11) | NA | 51 (11) | 60 (11) | NA |
| Day care attendance | 108 (30) | 262 (42) | 1.37 (0.99–1.89) | 34 (9) | 138 (22) | 1.56 (0.98–2.49) | 25 (7) | 98 (16) |
| 32 (9) | 79 (13) | 1.07 (0.67–1.71) |
| PCV-7 vaccination | 191 (38) | 179 (37) | NA | 79 (16) | 93 (19) | NA | 59 (12) | 64 (13) | NA | 47 (9) | 64 (13) | 1.46 (0.97–2.20) |
| Human rhinovirus | NA | 69 (11) | 103 (28) |
| 71 (12) | 52 (14) | NA | 61 (10) | 50 (14) | 1.16 (0.76–1.78) | ||
| Enterovirus | 267 (33) | 103 (60) |
| NA | 78 (10) | 45 (26) |
| 75 (9) | 36 (21) |
| ||
| Human bocavirus | 318 (37) | 52 (42) | NA | 127 (15) | 45 (37) |
| NA | 82 (10) | 29 (24) |
| ||
| WU polyomavirus | 320 (34) | 50 (45) | 1.11 (0.72–1.72) | 136 (16) | 36 (32) |
| 94 (11) | 29 (26) |
| NA | ||
| Human coronavirus | 355 (39) | 15 (19) |
| 153 (17) | 19 (24) | NA | 115 (13) | 8 (10) | NA | 101 (11) | 10 (13) | NA |
| Parainfluenza virus | 350 (38) | 20 (32) | NA | 155 (17) | 17 (27) |
| 111 (12) | 12 (19) | 1.55 (0.77–3.10) | 103 (11) | 8 (13) | NA |
| Adenovirus | 339 (37) | 31 (53) | 1.53 (0.86–2.74) | 154 (17) | 18 (31) | 1.76 (0.93–3.33) | 115 (12) | 8 (14) | NA | 106 (11) | 5 (9) | NA |
| Human parechovirus | 317 (36) | 53 (52) | 1.40 (0.89–2.20) | 134 (15) | 38 (38) |
| 110 (12) | 13 (13) | NA | 95 (11) | 16 (16) | NA |
| KI polyomavirus | 360 (38) | 10 (28) | NA | 166 (17) | 6 (17) | NA | 115 (12) | 8 (22) | 2.28 (0.96–5.40) | 108 (11) | 3 (8) | NA |
| RSV | 364 (38) | 6 (24) | NA | 168 (17) | 4 (25) | NA | 120 (12) | 3 (12) | NA | 108 (11) | 3 (12) | NA |
| Influenza virus | 367 (38) | 3 (18) | NA | 170 (18) | 2 (12) | NA | 122 (13) | 1 (6) | NA | 110 (11) | 1 (6) | NA |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; NA, not applicable (i.e., not included in the model for that particular virus or pooled group of viruses), RSV, respiratory syncytial virus.
Adjusted for age and all variables with a P value of <0.1 in univariate analysis.
Statistically significant associations are shown in bold.
Figure 1Graphical representation of interaction patterns.
Visualization of the partial correlations between bacteria and viruses (A) and epidemiologic drivers (risk factors) of those interactions (B). The patterns depicted here result from partial correlation network analysis and are visualized by Cytoscape. Bacteria are shown in blue, respiratory viruses in orange and risk factors in grey boxes. The solid lines represent associations with a p-value less than 0.01, the dashed lines represent associations with a p-value between 0.01 and 0.05. Green lines indicate positively correlated variables; red lines indicate negative correlations. The thickness of the line indicates the magnitude of the correlation. Abbreviations: SP, S. pneumoniae; HI, H. influenzae; MC, M. catarrhalis; SA, S. aureus; HRV, human rhinovirus, EV, enterovirus; HBoV, human bocavirus; WUPyV, WU polyomavirus; HCoV, human coronavirus; PIV, parainfluenza virus; HAdV, human adenovirus; IV, influenza virus; HPeV, human parechovirus; RSV, respiratory syncytial virus; AB, antibiotic use within 2 months before sampling; ‘crowding’ was entered into the model as a variable combining the presence of siblings (yes/no) and day care attendance (yes/no); 0 = no siblings and no day care attendance, 1 = siblings present, but not attending day care, or vice versa, and 2 = siblings present and attending day care.